{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:33:14Z","timestamp":1792783994197,"version":"4.5.0"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China (NSFC)","doi-asserted-by":"publisher","award":["81420108027"],"award-info":[{"award-number":["81420108027"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81273354"],"award-info":[{"award-number":["81273354"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Higher Education of China","award":["20110131130005"],"award-info":[{"award-number":["20110131130005"]}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"crossref","award":["ZR2009CM016"],"award-info":[{"award-number":["ZR2009CM016"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Science and Technology of Shandong Province","award":["2015ZDJS04001"],"award-info":[{"award-number":["2015ZDJS04001"]}]},{"name":"Science and Technology Development Project of Shandong Province","award":["2012GSF11804"],"award-info":[{"award-number":["2012GSF11804"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.ejmech.2016.02.051","type":"journal-article","created":{"date-parts":[[2016,2,25]],"date-time":"2016-02-25T05:10:11Z","timestamp":1456377011000},"page":"65-78","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Discovery of non-peptide small molecular CXCR4 antagonists as anti-HIV agents: Recent advances and future opportunities"],"prefix":"10.1016","volume":"114","author":[{"given":"Heng","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongwei","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boshi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2016.02.051_bib1","unstructured":"http:\/\/www.who.int\/campaigns\/aids-day\/2015\/en\/."},{"key":"10.1016\/j.ejmech.2016.02.051_bib2","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.2217\/fmb.10.67","article-title":"Role of CXCR4 in HIV infection and its potential as a therapeutic target","volume":"5","author":"Murakami","year":"2010","journal-title":"Future Microbiol."},{"key":"10.1016\/j.ejmech.2016.02.051_bib3","first-page":"751","article-title":"Entry inhibitors directed towards glycoprotein gp120: an overview on a promising target for HIV-1 therapy","volume":"20","author":"Flores","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2016.02.051_bib4","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1021\/jm900492g","article-title":"Twenty-six years of anti-HIV drug discovery: where do we stand and where do we go?","volume":"53","author":"Mehellou","year":"2010","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2016.02.051_bib5","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ijantimicag.2008.10.010","article-title":"Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV","volume":"33","author":"De Clercq","year":"2009","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejmech.2016.02.051_bib6","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1126\/science.272.5263.872","article-title":"HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor","volume":"272","author":"Feng","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2016.02.051_bib7","doi-asserted-by":"crossref","first-page":"5286","DOI":"10.1073\/pnas.89.12.5286","article-title":"Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event","volume":"89","author":"De Clercq","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2016.02.051_bib8","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/S0026-895X(24)26490-7","article-title":"Inhibition of HIV infection by bicyclams, highly potent and specific CXCR4 antagonists","volume":"57","author":"De Clercq","year":"2000","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2016.02.051_bib9","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.2174\/092986707781696618","article-title":"Small molecule CXCR4 chemokine receptor antagonists: developing drug candidates","volume":"14","author":"Khan","year":"2007","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2016.02.051_bib10","doi-asserted-by":"crossref","first-page":"9363","DOI":"10.1021\/jm300682j","article-title":"Chemokine receptor antagonists","volume":"55","author":"Pease","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2016.02.051_bib11","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1126\/science.1194396","article-title":"Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists","volume":"330","author":"Wu","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2016.02.051_bib12","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.bbamem.2006.11.002","article-title":"Regulation of CXCR4 signaling","volume":"1768","author":"Busillo","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejmech.2016.02.051_bib13","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/nrm1529","article-title":"Viral hijacking of G-protein-coupled-receptor signalling networks","volume":"5","author":"Sodhi","year":"2004","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2016.02.051_bib14","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1146\/annurev.iy.12.040194.003113","article-title":"The molecular biology of leukocyte chemoattractant receptors","volume":"12","author":"Murphy","year":"1994","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ejmech.2016.02.051_bib15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.7150\/thno.5376","article-title":"Small molecule inhibitors of CXCR4","volume":"3","author":"Debnath","year":"2013","journal-title":"Theranostics"},{"key":"10.1016\/j.ejmech.2016.02.051_bib16","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0165-6147(02)02064-3","article-title":"Chemokines, chemokine receptors and small-molecule antagonists: recent developments","volume":"23","author":"Onuffer","year":"2002","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2016.02.051_bib17","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1084\/jem.186.8.1395","article-title":"A\u00a0small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor","volume":"186","author":"Doranz","year":"1997","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ejmech.2016.02.051_bib18","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1084\/jem.186.8.1389","article-title":"A\u00a0small molecule CXCR4 inhibitor that blocks T cell line\u2013tropic HIV-1 infection","volume":"186","author":"Murakami","year":"1997","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ejmech.2016.02.051_bib19","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1128\/JVI.73.2.1719-1723.1999","article-title":"T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure","volume":"73","author":"Arakaki","year":"1999","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ejmech.2016.02.051_bib20","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1006\/bbrc.1998.9871","article-title":"A\u00a0low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140, Biochem","volume":"253","author":"Tamamura","year":"1998","journal-title":"Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2016.02.051_bib21","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1039\/b603818b","article-title":"Development of a linear type of low molecular weight CXCR4 antagonists based on T140 analogs","volume":"4","author":"Tamamura","year":"2006","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2016.02.051_bib22","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0140-6736(85)91162-6","article-title":"Antimoniotungstate (HPA 23) treatment of three patients with AIDS and one with prodrome","volume":"325","author":"Rozenbaum","year":"1985","journal-title":"J.\u00a0Lancet"},{"key":"10.1016\/j.ejmech.2016.02.051_bib23","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1155\/MBD.1997.173","article-title":"Antiviral metal complexes","volume":"4","author":"De Clercq","year":"1997","journal-title":"Met. Based Drugs"},{"key":"10.1016\/j.ejmech.2016.02.051_bib24","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nrd1134","article-title":"The bicyclam AMD3100 story","volume":"2","author":"De Clercq","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2016.02.051_bib25","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1128\/AAC.38.4.668","article-title":"Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100","volume":"38","author":"De Clercq","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2016.02.051_bib26","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0166-3542(95)00837-3","article-title":"The bicyclams, a new class of potent human immunodeficiency virus inhibitors, block viral entry after binding","volume":"29","author":"De Vreese","year":"1996","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2016.02.051_bib27","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1128\/AAC.41.12.2616","article-title":"Sensitivity of human immunodeficiency virus to bicyclam derivatives is influenced by the three-dimensional structure of gp120","volume":"41","author":"De Vreese","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2016.02.051_bib28","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0166-3542(97)00025-9","article-title":"Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin\/CXCR-4","volume":"35","author":"Schols","year":"1997","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2016.02.051_bib29","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0014-5793(02)03143-5","article-title":"Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4","volume":"527","author":"Hatse","year":"2002","journal-title":"FEBS Lett."},{"issue":"2004","key":"10.1016\/j.ejmech.2016.02.051_bib30","first-page":"1253","article-title":"Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection","volume":"37","author":"Hendrix","year":"1999","journal-title":"J.\u00a0Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.ejmech.2016.02.051_bib31","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.bcp.2008.12.014","article-title":"The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil)","volume":"77","author":"De Clercq","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2016.02.051_bib32","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1021\/jm990211i","article-title":"Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-azamacrocycles that inhibit HIV-1 and HIV-2 replication by antagonism of the chemokine receptor CXCR4","volume":"42","author":"Bridger","year":"1999","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2016.02.051_bib33","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1021\/jm980358u","article-title":"New bicyclam-AZT conjugates: design, synthesis, anti-HIV evaluation, and their interaction with CXCR-4 coreceptor","volume":"42","author":"Dessolin","year":"1999","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2016.02.051_bib34","doi-asserted-by":"crossref","first-page":"12996","DOI":"10.1128\/JVI.78.23.12996-13006.2004","article-title":"Inhibition of human immunodeficiency virus replication by a dual CCR5\/CXCR4 antagonist","volume":"78","author":"Princen","year":"2004","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ejmech.2016.02.051_bib35","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1021\/jm901530b","article-title":"Synthesis and structure-activity relationships of azamacrocyclic C-X-C chemokine receptor 4 antagonists: analogues containing a single azamacrocyclic ring are potent inhibitors of T-cell tropic (X4) HIV-1 replication","volume":"53","author":"Bridger","year":"2010","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2016.02.051_bib36","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1021\/bi0264770","article-title":"Metal ion enhanced binding of AMD3100 to Asp262 in the CXCR4 receptor","volume":"42","author":"Gerlach","year":"2003","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2016.02.051_bib37","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.bcp.2005.05.035","article-title":"AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor","volume":"70","author":"Hatse","year":"2005","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2016.02.051_bib38","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.bcp.2009.06.010","article-title":"Pharmacology of AMD3465: a small molecule antagonist of the chemokine receptor CXCR4","volume":"78","author":"Bodart","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2016.02.051_bib39","series-title":"Anti-HIV Activity Profile of AMD070, an Orally Bioavailable CXCR4 Antagonist","author":"Schols","year":"2003"},{"key":"10.1016\/j.ejmech.2016.02.051_bib40","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1021\/jm100073m","article-title":"Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication","volume":"53","author":"Skerlj","year":"2010","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2016.02.051_bib41","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1128\/AAC.00013-07","article-title":"Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects","volume":"51","author":"Stone","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2016.02.051_bib42","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.bmcl.2010.11.023","article-title":"Synthesis and SAR of novel CXCR4 antagonists that are potent inhibitors of T tropic (X4) HIV-1 replication","volume":"21","author":"Skerlj","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.02.051_bib43","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.bmcl.2011.01.021","article-title":"Design of novel CXCR4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication","volume":"21","author":"Skerlj","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.02.051_bib44","doi-asserted-by":"crossref","first-page":"5048","DOI":"10.1016\/j.bmcl.2009.07.037","article-title":"Amine substituted N-(1H-benzimidazol-2ylmethyl)-5,6,7,8-tetrahydro-8-quinolinamines as CXCR4 antagonists with potent activity against HIV-1","volume":"19","author":"Gudmundsson","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.02.051_bib45","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/j.bmcl.2010.02.053","article-title":"Novel N-substituted benzimidazole CXCR4 antagonists as potential anti-HIV agents","volume":"20","author":"Miller","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.02.051_bib46","doi-asserted-by":"crossref","first-page":"6399","DOI":"10.1016\/j.bmcl.2009.09.056","article-title":"Imidazopyridine-5,6,7,8-tetrahydro-8-quinolinamine derivatives with potent activity against HIV-1","volume":"19","author":"Gudmundsson","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.02.051_bib47","series-title":"Chemical Compounds","author":"Boggs","year":"2007"},{"key":"10.1016\/j.ejmech.2016.02.051_bib48","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1128\/AAC.01293-09","article-title":"Blockade of X4-tropic HIV-1 cellular entry by GSK812397, a potent noncompetitive CXCR4 receptor antagonist","volume":"54","author":"Jenkinson","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2016.02.051_bib49","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1016\/j.bmcl.2010.03.118","article-title":"Synthesis and SAR of novel isoquinoline CXCR4 antagonists with potent anti-HIV activity","volume":"20","author":"Miller","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.02.051_bib50","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1021\/ml400183q","article-title":"Discovery of tetrahydroisoquinoline-based CXCR4 antagonists","volume":"4","author":"Truax","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.02.051_bib51","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.bmcl.2010.02.030","article-title":"Synthesis of a novel tricyclic 1,2,3,4,4a,5,6,10b-octahydro-1,10-phenanthroline ring system and CXCR4 antagonists with potent activity against HIV-1","volume":"20","author":"Catalano","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"21","key":"10.1016\/j.ejmech.2016.02.051_bib52","doi-asserted-by":"crossref","first-page":"4950","DOI":"10.1016\/j.bmcl.2015.04.036","article-title":"Discovery of novel N-aryl piperazine CXCR4 antagonists","volume":"25","author":"Zhao","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.02.051_bib53","doi-asserted-by":"crossref","first-page":"7915","DOI":"10.1021\/jm801065q","article-title":"Orally bioavailable isothioureas block function of the chemokine receptor CXCR4 in\u00a0vitro and in\u00a0vivo","volume":"51","author":"Thoma","year":"2008","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2016.02.051_bib54","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1021\/jm9015729","volume":"53","author":"Wang","year":"2010","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2016.02.051_bib55","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1073\/pnas.0630420100","article-title":"A\u00a0duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity","volume":"100","author":"Ichiyama","year":"2003","journal-title":"Proc.Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2016.02.051_bib56","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1517\/13543770802553483","article-title":"Recent patents regarding the discovery of small molecule CXCR4 antagonists","volume":"19","author":"Mosley","year":"2009","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2016.02.051_bib57","series-title":"Nitrogenous Compounds and Antiviral Drugs Containing the Same","author":"Yamazaki","year":"2004"},{"key":"10.1016\/j.ejmech.2016.02.051_bib58","series-title":"Novel Nitrogenous Compound and Use Thereof","author":"Yamazaki","year":"2004"},{"key":"10.1016\/j.ejmech.2016.02.051_bib59","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1128\/AAC.01727-08","article-title":"The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100","volume":"53","author":"Murakami","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2016.02.051_bib60","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1124\/mol.60.1.164","article-title":"Mutation of Asp(171) and Asp(262) of the chemokine receptor CXCR4 impairs its coreceptor function for human immunodeficiency virus-1 entry and abrogates the antagonistic activity of AMD3100","volume":"60","author":"Hatse","year":"2001","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2016.02.051_bib61","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00430-012-0254-1","article-title":"Single oral administration of the novel CXCR4 antagonist, KRH-3955, induces an efficient and long-lasting increase of white blood cell count in normal macaques, and prevents CD4 depletion in SHIV-infected macaques: a preliminary study","volume":"202","author":"Nakasone","year":"2013","journal-title":"Med. Microbiol. Immunol."},{"key":"10.1016\/j.ejmech.2016.02.051_bib62","series-title":"Compound Containing Basic Group and Use Thereof","author":"Kokubo","year":"2008"},{"key":"10.1016\/j.ejmech.2016.02.051_bib63","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/cmdc.201100525","article-title":"Discovery of novel stem cell mobilizers that target the CXCR4 receptor","volume":"7","author":"Wu","year":"2012","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2016.02.051_bib64","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1021\/jm501772w","article-title":"Function-oriented development of CXCR4 antagonists as selective human immunodeficiency virus (HIV)-1 entry inhibitors","volume":"58","author":"Wu","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2016.02.051_bib65","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1021\/acsmedchemlett.5b00036","article-title":"Pyrazolo-piperidines exhibit dual inhibition of CCR5\/CXCR4 HIV entry and reverse transcriptase","volume":"6","author":"Cox","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.02.051_bib66","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1128\/AAC.04654-14","article-title":"Insights into the mechanism of inhibition of CXCR4: identification of Piperidinylethanamine analogs as anti-HIV-1 inhibitors","volume":"59","author":"Das","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2016.02.051_bib67","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1016\/j.bmcl.2008.05.092","article-title":"Identification of novel non-peptide CXCR4 antagonists by ligand-based design approach","volume":"18","author":"Ueda","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.02.051_bib68","doi-asserted-by":"crossref","first-page":"5655","DOI":"10.1021\/jm070679i","article-title":"Discovery of small molecule CXCR4 antagonists","volume":"50","author":"Zhan","year":"2007","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2016.02.051_bib69","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1021\/jm060025u","article-title":"Identification of a new class of low molecular weight antagonists against the chemokine receptor CXCR4 having the dipicolylamine-zinc(II) complex structure","volume":"49","author":"Tamamura","year":"2006","journal-title":"J.\u00a0Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523416301416?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523416301416?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T10:20:14Z","timestamp":1748773214000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523416301416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":69,"alternative-id":["S0223523416301416"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2016.02.051","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of non-peptide small molecular CXCR4 antagonists as anti-HIV agents: Recent advances and future opportunities","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2016.02.051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}